First Tracks Biotherapeutics (TRAX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on First Tracks Biotherapeutics (TRAX) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.09 of bullish evidence against -0.40 bearish.

First Tracks Biotherapeutics last closed at $32.99, -0.87% on the session.

Against the IVW growth benchmark the position is -1.79% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

16 graded predictions for TRAX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

First Tracks Biotherapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $1.19B.

StockMap tracks First Tracks Biotherapeutics as the 117th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite First Tracks Biotherapeutics ranks 293rd of 344 in the group, against a group median of -0.21.